Model-Based Meta-Analysis: An Important Tool for Making Quantitative Decisions During Drug Development
Author:
- 1 September 2012
- journal article
- editorial
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 92 (3) , 283-286
Abstract
Modeling during drug development is routinely used to integrate subject-level information, evaluate response, and inform clinical trials. Model-based meta-analysis (MBMA) combines aggregate safety and efficacy results from many trials. Because MBMA is based on results from large numbers of subjects, it increases the power to precisely detect small but clinically significant effects, providing a basis for quantitative drug development decisions and reducing time and cost. This Commentary describes an overview of MBMA and its application during drug development.Keywords
This publication has 9 references indexed in Scilit:
- A Dose–Response Meta-Analysis for Quantifying Relative Efficacy of Biologics in Rheumatoid ArthritisClinical Pharmacology & Therapeutics, 2011
- The Safety of Tiotropium — The FDA's ConclusionsNew England Journal of Medicine, 2010
- Longitudinal aggregate data model-based meta-analysis with NONMEM: approaches to handling within treatment arm correlationJournal of Pharmacokinetics and Pharmacodynamics, 2010
- Meta-analysis of individual patient data versus aggregate data from longitudinal clinical trialsClinical Trials, 2009
- Therapeutic Benefit of Eletriptan Compared to Sumatriptan for the Acute Relief of Migraine Pain — Results of a Model-Based Meta-Analysis that Accounts for EncapsulationCephalalgia, 2005
- The Promise and Problems of Meta-AnalysisNew England Journal of Medicine, 1997
- Discrepancies between Meta-Analyses and Subsequent Large Randomized, Controlled TrialsNew England Journal of Medicine, 1997
- Cumulative Meta-Analysis of Therapeutic Trials for Myocardial InfarctionNew England Journal of Medicine, 1992
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986